参考文献/References:
[1]刘宗超,李哲轩,张阳,等.2020全球癌症统计报告解读[J].肿瘤综合治疗电子杂志,2021,7(2):1-14.[2]Miller KD,Siegel RL,Lin CC,et al.Cancer treatment and survivorship statistics,2016[J].CA Cancer J Clin,2016,66(4):271-289.[3]Lagergren J,Smyth E,Cunningham D,et al.Oesophageal cancer[J].Lancet,2017,390(10110):2383-2396.[4]Shi Y,Qin R,Wang ZK,et al.Nanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinoma[J].Onco Targets Ther,2013,6:585-591.[5]Ando N,0zawa S,Kitagawa Y,et al.Improvement in the results of surgical treatment of advanced squamous esophageal carcinomaduring 15 consecutive years[J].Ann Surg,2000,232(2):225-232.[6]Tachibana M,Kinugasa S,Shibakita M,et al.Surgical treatment of superficial esophageal cancer[J].Langenbecks Arch Surg,2006,391(4):304-321.[7]陈龙奇,胡建昆,季加乎,等.食管胃结合部腺癌外科治疗中国专家共识(2018年版) [J].中华胃肠外科杂志,2018,21(9):961-975.[8]Siewert JR,Stein HJ,Feith M.Adenocarcinoma of the esophagogastric junction[J].Scand J Surg,2006,95(4):260-269.[9]田红岸,余开湖,郑小宁,等.携带125I粒子支架与普通支架治疗中晚期食管癌的临床对照研究[J].介入放射学杂志,2017(26):329-333.[10]Van Hagen P,Hulshof MC,van Lanschot JJ,et al.Preoporerative chemoradiotherpy for esophageal or junctional cancer[J].N Engl J Med,2012,366(22):2074-2084.[11]Sjoquist KM,Burmeister BH,Smithers BM,et al.Survivalafter neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis[J].Lancet Oncol,2011,2(7):681-692.[12]Yang H,Liu H,Chen Y,et al.Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus（NEOCRTEC5010）:APhase Ⅲ Multicenter,Randomized,Open-Label Clinical Trial[J].J Clin Oncol,2018,36(27):2796-2803.[13]Yang H, Liu H, Chen Y,et al.Neoadjuvant chemoradiotherapy followedby surgery versus surgery alone for locally advanced squamous cellcarcinoma of the esophagus (NEOCRTEC5010): A phase Ⅲ multicenter,randomized, open-label clinical trial [J]. J Clin Oncol, 2018, 36(27):2796-2803.[14]Pich O,Mui?觡os F,Lolkema MP,et al.The mutational footprints of cancer therapies[J].Nat Genet,2019,51(12):1732-1740.[15]Vallbohmer D,Holscher AH,DeMeester S,et al.A multicenterstudy of survival after neoadjuvant radiotherapy/chemotherapy andesophagectomy for vpT0N0M0R0 esophageal cancer[J].Ann Surg,2010,252(5):744-749.[16]张思维,郑荣寿,左婷好,等.中国食管癌死亡状况和生存分析[J].中华肿瘤杂志,2016,38(9):709-715.[17]何炜,樊青霞.局部晚期食管癌的围手术期治疗策略[J].中国肿瘤临床,2016,43(12):511-515.[18]Ajani JA,D’Amico TA,Bentrem DJ,et al.Esophageal andesophagogastric junction cancers, version 2. 2019, NCCN clinicalpractice guidelines in oncology[J].J Natl Compr Canc Netw,2019,17(7):855-883.[19]Jia RN,Shan TY,Wan LX,et al.X versus XELOX versus PF in definitiveconcurrent chemoradiotherapy (DCRT) for local advanced squamousesophageal cancer (ESCC): Update from a multicenter, open-label,randomizedⅢtrial, CRTCOESC trial[J].J Clin Oncol,2020,38(15_suppl):abstr4531.[20]Ai DS,Ye JJ,Chen Y,et al.Final results of a phaseⅢrandomized trial ofcomparison of three paclitaxelbased regimens concurrent with radiotherapy for patients with local advanced esophageal squamous cellcarcinoma[J].J Clin Oncol,2020,38(15_suppl):abstr4564.[21]Ito Y,Takeuchi H,Ogawa G,et al.A single-arm confirmatory study ofdefinitive chemoradiotherapy (dCRT) including salvage treatment inpatients (pts) with clinical (c) stage Ⅱ/Ⅲesophageal carcinoma (EC)(JCOG0909)[J].J Clin Oncol,2018,36(15_suppl):abstr4051.[22]Ito Y,Ogawa G,Kato K,et al.Final analysis of single-arm confirmatorystudy of definitive chemoradiotherapy including salvage treatment inpatients with clinica stageⅡ/Ⅲesophal carcinoma[J].J Clin Oncol,2020,38(15-suppl):abstr4545. [23]Cooper JS,Guo MD,Herskovic A,et al.Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group[J].JAMA,1999,281(17):1623-1627.[24]Zemanova M,Petruzelka L,Pazdro A,et al.Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up[J].Dis Esophagus,2010,23(2):160-167.[25]Huang J,Xu J,Chen Y,et al.Camrelizumab versusinvestigator’s choice of chemotherapy as second-line therapyfor advanced or metastatic oesophageal squamous cellcarcinoma (ESCORT):a multicentre, randomised, open-label,phase 3 study[J].Lancet Oncol,2020,21(6):832-842.[26]Kojima T,Shah MA,Muro K,et al.Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chem-otherapy in Advanced Esophageal Cancer[J].J Clin Oncol,2020:Jco2001888.[27]Kato K,Sun J,Shah M,et al.Pembrolizumab pluschemotherapy versus chemotherapy as first-line therapyin patients with advanced esophageal cancer: The phase 3KEYNOTE-590 study[C]//ESMO.2020.[28]Xu J,Bai Y,Xu N,et al.Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma[J].Clin Cancer Res,2020,26(17):4542-4550.[29]Zhang B,Qi L,Wang X,et al.Phase Ⅱ clinical trial usingcamrelizumab combined with apatinib and chemotherapy asthe first-line treatment of advanced esophageal squamous cellcarcinoma[J].Cancer Commun (Lond),2020,40(12):711-720.[30]Langer C,Gadgeel S,Borghaei H,et al.OA04.05 KEYNOTE-021:TMB and outcomes for carboplatin and pemetrexed with or without pembrolizumab for nonsquamousNSCLC[EB/OL].https://www.jto.org/article/S1556-0864(19)31109-8/fulltext,2019-10-01/2020-12-31.[31]Garassino M,Rodriguez-Abreu D,Gadgeel S,et al.OA04.06 Evaluation of TMB in KEYNOTE-189: pembrolizumab plus chemotherapy vs placebo plus chemotherapy fornonsq uamous NSCLC[EB/OL].https://www.jto.org/article/S 1556-0864(19)3 1110-4/abstract,2019-10-01/2020-12-31.
相似文献/References:
[1]阿布都艾尼窑米吉提.脊柱结核的手术治疗研究进展[J].医学信息,2018,31(01):64.[doi:10.3969/j.issn.1006-1959.2018.01.023]
Abdugeni·Mijit.Research Progress on Surgical Treatment of Spinal Tuberculosis[J].Journal of Medical Information,2018,31(18):64.[doi:10.3969/j.issn.1006-1959.2018.01.023]
[2]汪 兵,杜 铭.食管癌微创手术与机器人手术的研究[J].医学信息,2018,31(06):34.[doi:10.3969/j.issn.1006-1959.2018.06.012]
WANG Bing,DU Ming.Study on Minimally Invasive Surgery and Robotic Surgery for Esophageal Carcinoma[J].Journal of Medical Information,2018,31(18):34.[doi:10.3969/j.issn.1006-1959.2018.06.012]
[3]文虹杰,杨华刚,韩 涛,等.胫骨横向骨搬移术治疗糖尿病足的临床效果观察[J].医学信息,2018,31(07):184.[doi:10.3969/j.issn.1006-1959.2018.07.066]
WEN Hong-jie,YANG Hua-gang,HAN Tao,et al.Clinical Observation on the Treatment of Diabetic Foot with Transverse Tibial Bone Movement[J].Journal of Medical Information,2018,31(18):184.[doi:10.3969/j.issn.1006-1959.2018.07.066]
[4]韩林东,李 明.青少年特发性脊柱侧弯非手术治疗研究进展[J].医学信息,2018,31(08):28.[doi:10.3969/j.issn.1006-1959.2018.08.010]
HAN Lin-dong,LI Ming.Progress in Non-operative Treatment of Adolescent Idiopathic Scoliosis[J].Journal of Medical Information,2018,31(18):28.[doi:10.3969/j.issn.1006-1959.2018.08.010]
[5]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(18):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[6]许益芬.三维适型放疗与调强放疗在胸中段食管癌根治性放疗中的
剂量学比较[J].医学信息,2018,31(13):73.[doi:10.3969/j.issn.1006-1959.2018.13.021]
XU Yi-fen.Dosimetric Comparison of Three-dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Radical Radiotherapy of Middle Thoracic Esophageal Carcinoma[J].Journal of Medical Information,2018,31(18):73.[doi:10.3969/j.issn.1006-1959.2018.13.021]
[7]茹仙古丽·艾尔西丁,木拉提·哈米提,严传波,等.RF和C4.5决策树在食管癌图像分类中的研究[J].医学信息,2018,31(22):51.[doi:10.3969/j.issn.1006-1959.2018.22.015]
Roxangvl·Arxidin,Murat·Hamit,YAN Chuan-bo,et al.Research on RF and C4.5 Decision Tree in Image Classification of Esophageal Cancer[J].Journal of Medical Information,2018,31(18):51.[doi:10.3969/j.issn.1006-1959.2018.22.015]
[8]高 翔,夏 亮,杨亚斌.原发性闭角型青光眼的治疗[J].医学信息,2018,31(23):51.[doi:10.3969/j.issn.1006-1959.2018.23.015]
GAO Xiang,XIA Liang,YANG Ya-bin.Treatment of Primary Angleclosure Glaucoma[J].Journal of Medical Information,2018,31(18):51.[doi:10.3969/j.issn.1006-1959.2018.23.015]
[9]万 芳.以贫血为首发症状的消化道恶性肿瘤临床分析[J].医学信息,2018,31(24):175.[doi:10.3969/j.issn.1006-1959.2018.24.054]
WAN Fang.Clinical Analysis of Digestive Tract Malignancies with Anemia as the First Symptom[J].Journal of Medical Information,2018,31(18):175.[doi:10.3969/j.issn.1006-1959.2018.24.054]
[10]解 龙,练孝春,韩 涛,等.非哺乳期乳腺炎临床特征分析[J].医学信息,2019,32(06):128.[doi:10.3969/j.issn.1006-1959.2019.06.040]
XIE Long,LIAN Xiao-chun,HAN Tao,et al.Analysis of Clinical Features of Non-lactating Mastitis[J].Journal of Medical Information,2019,32(18):128.[doi:10.3969/j.issn.1006-1959.2019.06.040]